Marichal P, Gorrens J, Laurijssens L, Vermuyten K, Van Hove C, Le Jeune L, Verhasselt P, Sanglard D, Borgers M, Ramaekers F C, Odds F, Vanden Bossche H
Anti-Infectives Research Departments, Janssen Research Foundation, Beerse, Belgium.
Antimicrob Agents Chemother. 1999 Nov;43(11):2663-70. doi: 10.1128/AAC.43.11.2663.
The effects of itraconazole on ergosterol biosynthesis were investigated in a series of 16 matched clinical Candida albicans isolates which had been previously analyzed for mechanisms of resistance to azoles (D. Sanglard, K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille, Antimicrob. Agents Chemother., 39:2378-2386, 1995). Under control conditions, all isolates contained ergosterol as the predominant sterol, except two strains (C48 and C56). In isolates C48 and C56, both less susceptible to azoles than their parent, C43, substantial concentrations (20 to 30%) of 14alpha-methyl-ergosta-8,24(28)-diene-3beta,6alpha-dio l (3, 6-diol) were found. Itraconazole treatment of C43 resulted in a dose-dependent inhibition of ergosterol biosynthesis (50% inhibitory concentration, 2 nM) and accumulation of 3,6-diol (up to 60% of the total sterols) together with eburicol, lanosterol, obtusifoliol, 14alpha-methyl-ergosta-5,7,22,24(28)-tetraene-3betaol, and 14alpha-methyl-fecosterol. In strains C48 and C56, no further increase of 3,6-diol was observed after exposure to itraconazole. Ergosterol synthesis was less sensitive to itraconazole inhibition, as was expected for these azole-resistant isolates which overexpress ATP-binding cassette transporter genes CDR1 and CDR2. In addition to 3,6-diol, substantial amounts of obtusifolione were found after exposure to itraconazole. This toxic 3-ketosteroid was demonstrated previously to accumulate after itraconazole treatment in Cryptococcus neoformans and Histoplasma capsulatum but has not been reported in Candida isolates. Accumulation of obtusifolione correlated with nearly complete growth inhibition in these azole-resistant strains compared to that found in the susceptible parent strain, although the onset of growth inhibition only occurred at higher concentrations of itraconazole. ERG25 and ERG26 are the only genes assigned to the 4-demethylation process, of which the 3-ketoreductase is part. To verify whether mutations in these ERG25 genes contributed to obtusifolione accumulation, their nucleotide sequences were determined in all three related isolates. No mutations in ERG25 alleles of isolates C48 and C56 were found, suggesting that this gene is not involved in obtusifolione accumulation. The molecular basis for the accumulation of this sterol in these two strains remains to be established.
在一系列16株配对的临床白色念珠菌分离株中研究了伊曲康唑对麦角固醇生物合成的影响,这些分离株先前已针对对唑类的耐药机制进行了分析(D. Sanglard、K. Kuchler、F. Ischer、J. L. Pagani、M. Monod和J. Bille,《抗菌药物化疗》,39:2378 - 2386,1995年)。在对照条件下,除了两株菌株(C48和C56)外,所有分离株都以麦角固醇作为主要固醇。在分离株C48和C56中,它们对唑类的敏感性均低于其亲本C43,发现大量浓度(20%至30%)的14α - 甲基 - 麦角甾 - 8,24(28) - 二烯 - 3β,6α - 二醇(3,6 - 二醇)。用伊曲康唑处理C43导致麦角固醇生物合成呈剂量依赖性抑制(50%抑制浓度,2 nM),并积累3,6 - 二醇(高达总固醇的60%),同时伴有表鬼臼醇、羊毛甾醇、钝叶醇、14α - 甲基 - 麦角甾 - 5,7,22,24(28) - 四烯 - 3β醇和14α - 甲基 - 粪甾醇。在菌株C48和C56中,暴露于伊曲康唑后未观察到3,6 - 二醇的进一步增加。麦角固醇合成对伊曲康唑抑制的敏感性较低,正如对这些过表达ATP结合盒转运蛋白基因CDR1和CDR2的唑类耐药分离株所预期的那样。除了3,6 - 二醇外,暴露于伊曲康唑后还发现了大量的钝叶酮。这种有毒的3 - 酮类固醇先前已证实在伊曲康唑处理后在新型隐球菌和荚膜组织胞浆菌中积累,但在念珠菌分离株中尚未见报道。与敏感亲本菌株相比,这些唑类耐药菌株中钝叶酮的积累与几乎完全的生长抑制相关,尽管生长抑制仅在较高浓度的伊曲康唑时才出现。ERG25和ERG26是唯一与4 - 去甲基化过程相关的基因,3 - 酮还原酶是该过程的一部分。为了验证这些ERG25基因中的突变是否导致钝叶酮积累,在所有三个相关分离株中测定了它们的核苷酸序列。未发现分离株C48和C56的ERG25等位基因有突变,这表明该基因不参与钝叶酮的积累。这两种菌株中这种固醇积累的分子基础仍有待确定。